Atyr Pharma Overview
Get informed when a big investor buys or sells
+ Follow-11.89
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Atyr Pharma (LIFE) currently reports a P/E ratio of -11.89. That is below the Healthcare sector average of 21.65. Use the charts on this page to explore Atyr Pharma's P/E ratio history and peer comparisons.
Atyr Pharma's P/E ratio of -11.89 is lower than the Healthcare sector average of 21.65. That is roughly 154.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Atyr Pharma's market price to a fundamental measure such as earnings, sales, or book value. At -11.89, LIFE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -11.89, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.65. From there, open related valuation or income-statement pages for Atyr Pharma, and consider following LIFE for alerts when major investors trade the stock.
Atyr Pharma is classified in the Healthcare sector. On P/E ratio, it currently shows -11.89 versus a sector average near 21.65. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LIFE with unrelated industries.
